Kolon Life Science Inc - Asset Resilience Ratio

Latest as of March 2025: 1.22%

Kolon Life Science Inc (102940) has an Asset Resilience Ratio of 1.22% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Kolon Life Science Inc total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

₩7.33 Billion
≈ $4.97 Million USD Cash + Short-term Investments

Total Assets

₩601.96 Billion
≈ $407.94 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Kolon Life Science Inc's Asset Resilience Ratio has changed over time. See Kolon Life Science Inc (102940) shareholders funds for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Kolon Life Science Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Kolon Life Science Inc market cap and net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩7.33 Billion 1.22%
Short-term Investments ₩0.00 0%
Total Liquid Assets ₩7.33 Billion 1.22%

Asset Resilience Insights

  • Limited Liquidity: Kolon Life Science Inc maintains only 1.22% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Kolon Life Science Inc Industry Peers by Asset Resilience Ratio

Compare Kolon Life Science Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Theragen Etex Co.Ltd
KQ:066700
Pharmaceuticals 1.52%
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
Pharmaceuticals 4.82%
ST Pharm Co.Ltd
KQ:237690
Pharmaceuticals 7.72%
Oscotec Inc
KQ:039200
Pharmaceuticals 61.00%
Caregen Co.Ltd
KQ:214370
Pharmaceuticals 4.58%
NatureCell Co.Ltd
KQ:007390
Pharmaceuticals 0.00%
Mezzion Pharma Co.Ltd
KQ:140410
Pharmaceuticals 13.09%
Huons Global Co. Ltd
KQ:084110
Pharmaceuticals 5.46%

Annual Asset Resilience Ratio for Kolon Life Science Inc (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Kolon Life Science Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 2.96% ₩12.42 Billion
≈ $8.41 Million
₩419.56 Billion
≈ $284.33 Million
+0.54pp
2023-12-31 2.42% ₩7.48 Billion
≈ $5.07 Million
₩309.44 Billion
≈ $209.70 Million
+0.39pp
2022-12-31 2.03% ₩6.37 Billion
≈ $4.32 Million
₩314.12 Billion
≈ $212.87 Million
-9.87pp
2021-12-31 11.89% ₩27.91 Billion
≈ $18.91 Million
₩234.66 Billion
≈ $159.02 Million
+5.84pp
2020-12-31 6.05% ₩15.03 Billion
≈ $10.19 Million
₩248.34 Billion
≈ $168.29 Million
-1.46pp
2019-12-31 7.51% ₩20.91 Billion
≈ $14.17 Million
₩278.29 Billion
≈ $188.60 Million
+1.41pp
2018-12-31 6.10% ₩37.77 Billion
≈ $25.60 Million
₩618.90 Billion
≈ $419.42 Million
-4.89pp
2017-12-31 11.00% ₩78.83 Billion
≈ $53.42 Million
₩716.80 Billion
≈ $485.76 Million
-27.88pp
2016-12-31 38.88% ₩137.85 Billion
≈ $93.42 Million
₩354.57 Billion
≈ $240.29 Million
--
pp = percentage points

About Kolon Life Science Inc

KQ:102940 Korea Pharmaceuticals
Market Cap
$453.05 Million
₩668.52 Billion KRW
Market Cap Rank
#13062 Global
#428 in Korea
Share Price
₩58600.00
Change (1 day)
-3.30%
52-Week Range
₩24250.00 - ₩70800.00
All Time High
₩163572.85
About

Kolon Life Science Inc. provides biopharmaceuticals, active pharmaceutical ingredients, pyrithione antimicrobials, and water solutions primarily in South Korea. Its biopharmaceutical product under development comprise KLS-1020, a cancer vaccine; KLS-3021, a oncolytic viral therapy; and KLS-2031 for treatment for neuropathic pain. The company also provides active pharmaceutical ingredients for ant… Read more